Search results for "type 1"

showing 10 items of 540 documents

Celiac disease and endocrine autoimmunity.

2015

<b><i>Background:</i></b> Celiac disease (CD) is a small-intestinal inflammatory disease that is triggered by the ingestion of the storage proteins (gluten) of wheat, barley and rye. <b><i>Key Messages:</i></b> Endocrine autoimmunity is prevalent in patients with CD and their relatives. The genes that predispose to endocrine autoimmune diseases, e.g. type 1 diabetes, autoimmune thyroid diseases, and Addison's disease, i.e. DR3-DQ2 and DR4-DQ8, are also the major genetic determinants of CD, which is the best understood HLA-linked disease. Thus, up to 30% of first-degree relatives both of patients with CD and/or endocrine autoimmunity are affect…

medicine.medical_specialtyTissue transglutaminaseAutoimmunityEndocrine SystemDiseasemedicine.disease_causeAutoantigensAutoimmunityImmune systemInternal medicinemedicineEndocrine systemHumanschemistry.chemical_classificationType 1 diabetesbiologybusiness.industryThyroidGastroenterologynutritional and metabolic diseasesGeneral Medicinemedicine.diseaseGlutenCeliac DiseaseEndocrinologymedicine.anatomical_structurechemistrybiology.proteinbusinessDigestive diseases (Basel, Switzerland)
researchProduct

Higher cardiometabolic risk in idiopathic versus autoimmune type 1 diabetes: A retrospective analysis

2018

Abstract Background Idiopathic type 1 diabetes mellitus (IDM) is characterized by an onset with insulinopenia and ketoacidosis with negative β-cell autoimmunity markers and lack of association with HLA. The aim of the study is to compare the clinical and metabolic parameters, the macro and microvascular complications, the adipose tissue dysfunction and the insulin secretion and sensitivity indexes in patients with IDM and autoimmune type 1 diabetes mellitus (ADM) at clinical onset. Methods Thirty patients with IDM and 30 with ADM, matched for age and gender, were retrospectively analyzed. BMI, waist circumference, lipids, glycemia, HbA1c, insulin requirement, glutamic oxaloacetic and glutam…

medicine.medical_specialtyType 1 diabetemedicine.medical_treatmentEndocrinology Diabetes and MetabolismAdipose tissue030209 endocrinology & metabolismType 2 diabetes030204 cardiovascular system & hematologyGastroenterologyCardiovascular risk factorSettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineInsulin resistanceInternal medicineDiabetes mellitusmedicineInternal Medicinec-Peptideslcsh:RC620-627Cardiovascular risk factorsType 1 diabetesC-Peptidebusiness.industryInsulinResearchInsulin secretionInsulin resistancemedicine.diseaseKetoacidosislcsh:Nutritional diseases. Deficiency diseasesType 1 diabetesSteatosisC-Peptides; Cardiovascular risk factors; Insulin resistance; Insulin secretion; Type 1 diabetes; Internal Medicine; Endocrinology Diabetes and Metabolismbusiness
researchProduct

Associations between type of treatment and illness-specific locus of control in type 1 diabetes patients

1993

Abstract This study examined differences in diabetes-specific locus of control beliefs of 82 insulin-treated Type I diabetes patients undergoing either conventional therapy (CT), intensified conventional therapy (ICT) or continuous subcutaneous insulin infusion (CSII). Compared to CT with its adherence to a strict regimen, ICT and CSII allow a much greater flexibility in timing of meals and daily activities. On the other hand, such flexibility requires a much more active role of the patient. The hypotheses of higher internality and lower powerful others locus of control beliefs in ICT and CSII patients than in CT patients could be supported for powerful others locus of control only. A one-y…

medicine.medical_specialtyType 1 diabetesActivities of daily livingbusiness.industrymedia_common.quotation_subjectPublic Health Environmental and Occupational HealthFlexibility (personality)General MedicineGeneral Chemistrymedicine.diseaseSurgerySubcutaneous insulinRegimenLocus of controlInternal medicinemedicinePersonalityPoor glycaemic controlbusinessApplied Psychologymedia_commonPsychology & Health
researchProduct

A low-carbohydrate high-fat diet initiated promptly after diagnosis provides clinical remission in three patients with type 1 diabetes

2020

medicine.medical_specialtyType 1 diabetesEndocrinologybusiness.industryEndocrinology Diabetes and MetabolismInternal medicineLow carbohydrate high fatInternal MedicinemedicineGeneral Medicinemedicine.diseasebusinessGastroenterologyDiabetes & Metabolism
researchProduct

Fatty liver indexandhepatic steatosis index for prediction ofnon-alcoholic fatty liver disease in type 1 diabetes

2017

Background and Aim Little is known about the diagnostic value of hepatic steatosis index (HSI) and fatty liver index (FLI), as well as their link to metabolic syndrome in type 1 diabetes mellitus. We have screened the effectiveness of FLI and HSI in an observational pilot study of 40 patients with type 1 diabetes. Methods FLI and HSI were calculated for 201 patients with type 1 diabetes. Forty patients with FLI/HSI values corresponding to different risk of liver steatosis were invited for liver magnetic resonance study. In-phase/opposed-phase technique of magnetic resonance was used. Accuracy of indices was assessed from the area under the receiver operating characteristic curve. Results Tw…

medicine.medical_specialtyType 1 diabetesWaistHepatologyReceiver operating characteristicbusiness.industryfungiFatty liverGastroenterologymedicine.diseaseLikelihood ratios in diagnostic testingNephropathy03 medical and health sciences0302 clinical medicineEndocrinology030220 oncology & carcinogenesisInternal medicinemedicine030211 gastroenterology & hepatologyMetabolic syndromeSteatosisbusinessJournal of Gastroenterology and Hepatology
researchProduct

The physiological impact of proinsulin C-peptide

1999

Abstract The proinsulin C-peptide fulfills an important function in the biosynthesis of insulin by facilitating the formation of the correct secondary and tertiary structure of the hormone. C-peptide and insulin are released in equimolar amounts to the circulation but C-peptide has generally been considered to be biologically inert. However, recent studies indicate that C-peptide administration to type 1 diabetes patients is accompanied by improved renal function, amelioration of autonomic dysfunction, stimulated tissue glucose utilization and augmented skin and muscle blood flow. The cellular mechanisms underlying these effects may be related to C-peptide's capacity to stimulate both Na + …

medicine.medical_specialtyType 1 diabetesbiologyC-peptideInsulinmedicine.medical_treatmentATPasebiology.organism_classificationmedicine.diseasePathology and Forensic Medicinechemistry.chemical_compoundEndocrinologychemistryEnosPhysiology (medical)Internal medicinemedicinebiology.proteinNa+/K+-ATPaseHormoneProinsulinPathophysiology
researchProduct

Diabetic Retinopathy. Association with Metabolic Compensation, Duration of Diabetes and Other Micro and Macrovascular Complications in Patients with …

2020

Summary Introduction Diabetic retinopathy (DR) is a severe complication that can lead to complete vision loss and still is one of the main blindness-causing reasons among patients with type 1 diabetes mellitus (T1DM). DR as a complication can cause vision loss to people at their working age. More than 90% of patients with type 1 diabetes will develop DR by 20 years post diagnosis (Leslie R. Dye, 2018). DR is more likely to develop in patients with T1DM (Kanski's Clinical Ophthalmology, 2016). This complication can be very serious speaking of the ability to see. Sometimes vitrectomy plays a vital role in the management of severe complications of DR at its end-stage (Myron Yanoff et al., 2020…

medicine.medical_specialtyType 1 diabetesbusiness.industry030209 endocrinology & metabolismDiabetic retinopathymedicine.disease03 medical and health sciences0302 clinical medicineInternal medicineDiabetes mellitusmedicineGeneral Materials ScienceIn patient030212 general & internal medicineDuration (project management)businessActa Chirurgica Latviensis
researchProduct

Abstract 412: The Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin Improves Diabetic Complications in the Streptozotocin Type 1 Diabetes Mellit…

2014

Objectives: In diabetes, cardiovascular complications are associated with endothelial dysfunction and oxidative stress. Empagliflozin (Empa), as a selective sodium-glucose co-transporter 2 inhibitor (SGLT2i) in clinical development, offers a promising novel approach for the treatment of type 2 diabetes by enhancing urinary glucose excretion. The aim of the present study was to test whether treatment with Empa could improve endothelial dysfunction in type I diabetic rats via reduction of glucotoxicity and associated oxidative stress. Research Design and Methods: Type I diabetes in Wistar rats was induced by an intravenous injection of streptozotocin (60 mg/kg). One week after injection Empa…

medicine.medical_specialtyType 1 diabetesbusiness.industryType 2 diabetesmedicine.diseasemedicine.disease_causeStreptozotocinEndocrinologyInternal medicineDiabetes mellitusmedicineEmpagliflozinEndothelial dysfunctionSGLT2 InhibitorCardiology and Cardiovascular MedicinebusinessOxidative stressmedicine.drugArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct

Changes in serum lipid and lipoprotein concentrations and compositions at birth and after 1 month of life in macrosomic infants of insulin-dependent …

1999

The aim of this study was to determine whether macrosomia related to maternal diabetes alters lipoprotein metabolism and whether these abnormalities still persist or regress after 1 month of life. Serum lipoprotein compositions and concentrations as well as serum lipid fatty acid compositions were investigated in macrosomic infants (birth weight = 4840 +/- 105 g at term) of insulin-dependent diabetic mothers at birth and after 1 month of life, and were compared to those of control infants (birth weight = 3400 +/- 198 g at term) of healthy mothers. Compared to controls, at birth, macrosomic newborns had higher serum lipids, apolipoprotein A-I and B-100, and lipoprotein (very low density lipo…

medicine.medical_specialtyVery low-density lipoproteinApolipoprotein BBirth weightLipoproteinsPregnancy in DiabeticsBlood lipidsFetal Macrosomiachemistry.chemical_compoundPregnancyReference ValuesInternal medicineDiabetes mellitusmedicineHumanschemistry.chemical_classificationbiologybusiness.industryFatty AcidsInfant NewbornFatty acidmedicine.diseaseLipidsEndocrinologyDiabetes Mellitus Type 1chemistryLow-density lipoproteinCase-Control StudiesPediatrics Perinatology and Child Healthbiology.proteinlipids (amino acids peptides and proteins)FemalebusinessLipoproteinEuropean journal of pediatrics
researchProduct

Improved Cardiovascular and Cardiometabolic Risk in Patients With Type 1 Diabetes and Autoimmune Polyglandular Syndrome Switched From Glargine to Deg…

2018

Background: Cardiovascular disease is a frequent complication of type 1 diabetes (T1D). We evaluated the effectiveness of switching from glargine to degludec in reducing the cardiovascular risk factors, the Framingham risk score (FRS) and visceral adiposity index (VAI) in patients with T1D and autoimmune polyglandular syndrome (APS).Methods: We selected 66 T1D outpatients who had been on stable treatment with glargine for at least 5 years. Among them, 30 patients maintained glargine (group A), while 36 were switched to degludec (group B) for 12 months. At baseline and after 12 months of observation, clinical and metabolic parameters, insulin dose, 30-days blood glucose (BG) self monitoring,…

medicine.medical_specialtyWaistType 1 diabetetype 1 diabetesmedicine.medical_treatmentEndocrinology Diabetes and Metabolism030209 endocrinology & metabolism030204 cardiovascular system & hematologyGroup AGastroenterologylcsh:Diseases of the endocrine glands. Clinical endocrinologyGroup BSettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicinemedicineIn patientGlargineOriginal ResearchType 1 diabetesFramingham Risk Scorelcsh:RC648-665business.industryInsulinmedicine.diseaseCardiovascular riskInsulin therapyComplicationbusinessHypoglycaemiaDegludecFrontiers in Endocrinology
researchProduct